FTSE MIB
34.244,81 +257,91 (+0,76%) Dow Jones
38.921,87 +69,60 (+0,18%) Nasdaq
16.375,15 +25,90 (+0,16%) Nikkei 225
38.835,10 +599,03 (+1,57%) Petrolio
78,19 -0,29 (-0,37%) Bitcoin EUR
59.032,29 +103,66 (+0,18%)
Sensei Biotherapeutics, Inc. (SNSE)
| Chiusura precedente | 1,8400 |
| Aperto | 1,8100 |
| Denaro | 1,2400 x 200 |
| Lettera | 2,2100 x 200 |
| Min-Max giorno | 1,7191 - 1,8100 |
| Intervallo di 52 settimane | 0,5100 - 1,9200 |
| Volume | |
| Media Volume | 167.447 |
| Capitalizzazione | 45,271M |
| Beta (5 anni mensile) | 0,16 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,2200 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,67 |
GlobeNewswireSensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety data expected in the fourth quarter of 2023 and topline monotherapy data expected in 2024 - - New guidance for initial combination PK and safety data expected in the first quarter of 2024, with preliminary anti-tumor activity data expected in 2024 - BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sensei Bio
- GlobeNewswire
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile - - Mechanistic mouse data show SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype - BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today will present new prec
- GlobeNewswire
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy
